Abstract:ABSTRACT Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar and excellent intrapulmonary penetration, supporting the use of this new antibiotic combination in the treatment of hospital-acquired pneumonia. This study evaluated the in vivo efficacy of cefepime/enmetazobactam in a murine neutropenic pneumonia model infected with various OXA-48-producing K. pneumoniae strains. Mice were subcutaneously administered with cefepime (100 mg/kg/q2h), alone or combined with enmetazobactam (30 mg/kg/q2h), or intraperitoneally with meropenem (100 mg/kg/q2h) at 2 h post-infection. Mice were euthanized at 26 h post-infection for bacterial enumeration in lungs and spleen. A robust growth was achieved in untreated control mice. Cefepime alone or meropenem had no effect on reducing the bacterial burden in lungs after a 24-h period of treatment. The addition of enmetazobactam to cefepime resulted in a 2-log 10 CFU/g bioburden reduction in lungs compared to 26-h controls for all strains, including the strain harboring the highest MIC (= 8 μg/mL) to cefepime/enmetazobactam. When changes of bacterial burden were assessed relative to 2-h controls, bacterial stasis was observed. These data highlight the limited in vivo activity of meropenem against OXA-48-producing Enterobacterales despite in vitro susceptibility. Conversely, cefepime/enmetazobactam with a human-mimicking regimen demonstrated a significant antibacterial effect in the pneumonia model induced by three OXA-48-producing K. pneumoniae strains, compared with cefepime or meropenem at 24 h post-infection. Therefore, cefepime/enmetazobactam may be a new alternative for lung infections due to Enterobacterales producing OXA-48. IMPORTANCE Third-generation cephalosporin-resistant Klebsiella pneumoniae with extended-spectrum β-lactamases as principal resistance determinants are classified as critical priority pathogens. Their increasing occurrence has led clinicians to widely use carbapenems. Accordingly, carbapenem resistance in Klebsiella pneumoniae has spread in recent decades across several countries, and OXA-48-like carbapenemases are one of the main determinants of carbapenem resistance in Enterobacterales. Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination that demonstrated excellent intrapulmonary penetration, supporting its use in the treatment of pneumonia. This study examined the efficacy of enmetazobactam, in combination with cefepime, compared to carbapenems for OXA-48-producing Klebsiella pneumoniae in a 24-h murine neutropenic pneumonia model. The combination showed a bacteriostatic effect using the 2-h controls as reference. Compared to 24-h controls, and to cefepime or meropenem monotherapies, the co-administration of enmetazobactam with cefepime demonstrated a pronounced in vivo bactericidal activity against cefepime-non-susceptible K. pneumoniae isolates with cefepime/enmetazobactam MICs up to 8 μg/mL in this model.

Treatment effects of the combination of cefuroxime and tazobactam against mouse septicemia infected by β-lactamases producing strains

Antibacterial Activities of Different Concentration Ratio of Cefotaxim-Sulbactam Against the Pathogenic Microorganisms

A multicenter study on the in vitro antibacterial activity of cefoselis against common clinical bacteria

In Vitro Antibacterial Activities of Different Ratios from Matching Cefuroxime/tazobactam Against Clinical Isolates

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo--Lactamase

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae

In vivo antibacterial effect of cefathiamidine against mouse septicemia

Antibacterial activity study of several β-lactam/β-lactamase inhibitor combinations in vitro

In vivo activity of cefcapene proxetil in the experimental motel of mouse septicemia infected by bacteria

In vitro activity of different ratios from matching cefotaxime/culbactam

Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection

In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii

Antibacterial Effect Evaluation of Moxalactam Against Extended-Spectrum Beta-Lactamase-producing Escherichia Coli and Klebsiella Pneumoniae with in Vitro Pharmacokinetics/pharmacodynamics Simulation

In vivo activity of antibiotic 89-07 combined with flomoxef in the experimental therapy of mouse septicemia infected by mec A gene positive MRSA

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Stability of cefuroxime/tazobactam to β-lactamases and ability of tazobactam in preventing hydrolysis

In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii

Synergistic Activity of Tienam and Netilmycin in a Combination Therapy in Experimental MRSA Infection of Mice

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae